View Older Stories View More Recent Stories

Aug 3, 2017 03:28PM AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
Jul 28, 2017 10:57AM European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jun 23, 2017 08:47AM AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
May 4, 2017 09:00AM AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week®
Apr 21, 2017 01:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Apr 20, 2017 07:31AM AbbVie (ABBV) G/P Achieved 99% SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
Apr 20, 2017 07:30AM AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
Mar 14, 2017 08:03AM AbbVie's (ABBV) G/P Regimen for HCV Granted Priority Review in Japan
Mar 14, 2017 08:00AM AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Feb 27, 2017 04:00AM AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic
Feb 2, 2017 08:04AM AbbVie (ABBV) Granted FDA Priority Review for Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C
Feb 2, 2017 08:00AM U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jan 24, 2017 04:00AM European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chron
Jan 9, 2017 07:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japane
Dec 19, 2016 08:03AM AbbVie (ABBV) Submits NDA for Regimen of Glecaprevir/Pibrentasvir to Treat Hepatitis C
Dec 19, 2016 08:00AM AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Nov 15, 2016 08:00AM AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
Nov 11, 2016 08:06AM AbbVie (ABBV) Updates on Glecaprevir/Pibrentasvir Treatment Regiment in HCV; High SVR12 Rates Noted at 8 Weeks
Nov 11, 2016 08:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C
Sep 30, 2016 08:01AM AbbVie's (ABBV) Glecaprevir/Pibrentasvir HCV Regiment Receives FDA Breakthrough Therapy Designation
Sep 30, 2016 08:00AM AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Sep 23, 2016 05:59AM AbbVie (ABBV) Presents VIEKIRAX + EXVIERA Phase 3 Data in HCV; Sustained Virologic Response Rates Noted
Sep 23, 2016 04:00AM AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Jul 25, 2016 05:06PM AbbVie's (ABBV) VIEKIRA XR NDA Approved by U.S. FDA
Jul 25, 2016 05:04PM AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Jul 25, 2016 06:18AM AbbVie (ABBV) Receives Positive CHMP Opinion on VIEKIRAX in GT4 HCV (ENTA)
Jul 25, 2016 04:00AM CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrh
Apr 25, 2016 09:03AM AbbVie (ABBV) Receives FDA Approval of Viekira Pak sNDA for Use Without RBV
Apr 25, 2016 09:00AM AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic H
Apr 18, 2016 06:46AM AbbVie (ABBV) Announces Positive Data from ABT-493, ABT-530 Phase 2 in HCV Genotypes 1 - 6 (ENTA)
Apr 16, 2016 01:00AM AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6
Apr 15, 2016 06:38AM AbbVie (ABBV) Issues Positive Update on ABT-493 and ABT-530 w/ RBV in HCV GT1 (ENTA)
Apr 15, 2016 01:00AM AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Apr 15, 2016 01:00AM AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry
Apr 14, 2016 01:00AM AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatm
Mar 30, 2016 07:00AM AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 201
Feb 26, 2016 09:35AM AbbVie (ABBV) Announces Positive CHMP Opinion for VIEKIRAX Without Ribavirin in HCV
Feb 26, 2016 09:33AM AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype
Jan 11, 2016 07:00AM AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
Jan 7, 2016 09:02AM AbbVie (ABBV) Says FDA Gives Priority Review for Supplemental New Drug Application for VIEKIRA PAK
Jan 7, 2016 09:00AM U.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chro
Dec 2, 2015 08:00AM AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic H
Nov 16, 2015 09:00AM AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
Nov 14, 2015 09:01AM AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis
Oct 1, 2015 01:02PM AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The
Sep 28, 2015 02:00AM AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Jun 24, 2015 06:00AM AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
May 26, 2015 07:00PM AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis
Apr 25, 2015 10:00AM AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015
Apr 24, 2015 12:45AM U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C
View More Recent Stories View Older Stories